Clinical Pharmacology & Therapeutics Online Course

Explore the evolution of clinical trials from ancient experiments by Nebuchadnezzar to James Lind's controlled study, highlighting the scurvy vitamin C trials and the shift to modern, rapid vaccine development.

Trace the history of pharmacopoeia standards and drug regulation from US Pharmacopeia (1820) to 1902 Biologic Control Act, 1906 Food and Drug Act, and the Tuskegee syphilis study.

Trace the 1937 sulfanilamide tragedy, where a raspberry-flavored elixir with polyethylene glycol caused mass poisonings and over 100 deaths, leading to the 1938 Food, Drug and Cosmetic Act.

Explore blinding in clinical trials: single, double, and triple, where patients, doctors, and statisticians remain unaware of treatment versus placebo, tracing origins to early randomized studies.

Understand how the Nuremberg trial produced the Nuremberg Code, mandating voluntary informed consent and the right to withdraw to protect subjects in clinical trials.

Trace the thalidomide disaster to the Kefauver Harris Amendment of 1962, empowering the FDA to regulate drug testing, marketing, advertising, and enforce safety via pharmacovigilance and Declaration of Helsinki.

Established in 1974, the National Research Act created IRBs to protect human subjects in clinical trials, rooted in the Tuskegee study, with Belmont Report principles guiding informed consent.

International Council for Harmonization unites regulatory authorities from Europe, Japan, and the United States to create global GCP guidelines that protect patient safety, established from its April 1990 Brussels meeting.

Explore the ICH organization structure, including the steering committee, global cooperation, and Meddra as the standard medical dictionary, plus four working groups guiding quality, safety, efficacy, and multidisciplinary guidelines.

Learn the 18 efficacy guidelines, with a focus on good clinical practices (GCP), ethics, and pharmacovigilance to protect participant safety and ensure compliant trial data for regulatory review.

Differentiate adverse drug reactions from adverse events and explain key clinical trial terms such as blinding, essential documents, and investigational product within regulatory and ethics oversight.

Explain who counts as an investigator, differentiate primary and co-investigators, and define sites and participants in a clinical trial.

Explore good clinical practice guidelines and terms, including protocol and amendments, regulatory authorities, serious adverse events, adverse drug reactions, source documents and data, CRFs, and subject identification in clinical trials.

Explains the 13 ich gcp principles, covering declaration of helsinki, risk-benefit assessment, trial safety, ethics committee, protocol adherence, informed consent, data recording, confidentiality, product handling, and quality procedures.

Understand the IRB's role in protecting participants, approving documents and protocols, and safeguarding children and prisoners, while recognizing the investigator's duties to conduct trials per the trial agreement and protocol.

The sponsor initiates the clinical trial, provides financial support, owns the drug, and ensures protocol, investigator brochure, and essential documents align with ICH GCP and a risk-based approach.

Trace the history of drug discovery from herbal and serendipitous beginnings to the antibiotic era and biotech commercialization, highlighting the stages from target selection to clinical trials.

Explore preclinical trials conducted on animals to assess drug safety profile and pharmacokinetics, including devices and gene therapies, and learn about the investigational new drug application for phase one trials.

Explore the phases of clinical trials from phase zero to phase four, including IND and NDA applications, microdosing, and post-marketing surveillance.

Explore observational and interventional clinical trial designs, including cohort, case control, and cross sectional studies, plus randomization, blinding, bias, and major designs like parallel group, crossover, and factorial trials.

Explore OECD guidelines for acute oral toxicity testing, including LD50/LC50 calculations and humane alternatives like cell cultures, plus sighting studies and the organization's global role.

Adverse drug effects are undesirable responses, classified as predictable and unpredictable, including side effects, secondary effects, and toxic effects; some side effects are unavoidable at therapeutic doses.

Learn about acute oral toxicity testing in animals, with definitions of acute, subacute, subchronic, and chronic toxicity and symptoms like tremors, salivation, convulsions, and weight loss.

Explain ld50 and lc50 as measures of toxicity, defining lethal dose 50 and lethal concentration 50 as the dose and air concentration that kill 50% of test animals.

Explore how OECD guidelines promote humane oral toxicity testing by using toxic-dose concepts, monitoring pain onset, and reducing animal suffering through methods in guidelines 401, 420, and 423.

Explores alternatives to animal testing, including in vitro methods with human cell cultures. Examines virtual trials, tissue and stem cell testing, genetic methods, and noninvasive MRI/CT assessments.

Examine OECD guidelines for acute oral toxicity testing, including guideline 401 for conventional acute toxicity testing, the fixed dose procedure, the acute toxic class method, and the up‑and‑down procedure.

The OECD 401 and 420 guidelines describe oral toxicity testing by repeated dosing in rodents, observing mortality and toxicity signs, with 420 using fixed dose levels to reduce suffering.